Results 71 to 80 of about 22,658,601 (368)
ABSTRACT In pediatric patients, T‐cell lymphoblastic lymphoma (T‐LBL) survival exceeds 80%. Relapse remains associated with limited curative options. Frontline treatment is largely extrapolated from T‐cell acute lymphoblastic leukemia (T‐ALL) treatment, reflecting the ongoing debate, whether both entities represent distinct diseases or variants within ...
Marie C. Heider +4 more
wiley +1 more source
Board of Regents institution, is an Equal Opportunity/Affirmative Action University. It is committed to education of a non-racially identifiable student body.
M. Tabbakh
semanticscholar +1 more source
ABSTRACT Background Blinatumomab is a bispecific T‐cell engager approved for the treatment of pediatric B‐cell acute lymphoblastic leukemia (B‐ALL). Outpatient home infusion reduces hospitalization burden and optimizes resource utilization, but is logistically challenging.
Angela Parra del Riego +10 more
wiley +1 more source
ON THE OCCASION OF THE 70TH BIRTH ANNIVERSARY OF ACADEMICIAN VADIM IVANOVICH MAZUROV
.
Issue Editor
doaj +2 more sources
In this installment of At Issue, two of CiSE's editorial board members describe the magazine's current and future Web presence. We start with Bill Feiereisen's discussion of science on the Web and what it could mean for CiSE ("Are We There Yet?") and end with George Thiruvathukal's discussion of the challenges therein ("If We Build It, Will They Come?")
Feireisen, Bill +1 more
openaire +2 more sources
ABSTRACT Background 131I‐metaiodobenzylguanidine (131I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment.
Benjamin J. Lerman +7 more
wiley +1 more source
Covid-19, communication and religion: Looking back at the first wave of the coronavirus pandemic
Norberto González Gaitano
doaj +1 more source

